Prognostic value of disseminated tumor cells in unresectable pancreatic ductal adenocarcinoma: a prospective observational study

Oddmund Nordgård1,2*, Morten Lapin1, Kjersti Tjensvoll1, Satu Ol tedal1, Karin Hestnes Edland1, Nicolay Bore Neverdahl2, Dmitrij Fostenes2, Herish Garresori1, Nils Glenjen3, Rune Smaaland1,4 and Bjørnar Gilje1

Abstract

Background: Although pancreatic ductal adenocarcinoma (PDAC) rarely metastasizes to the skeleton, disseminated tumor cells have been detected in bone marrow samples from patients with this disease. The prognostic value of such findings is currently unclear. Thus, the current study aimed to clarify the prognostic information associated with disseminated tumor cell detection in samples from patients with PDAC.

Methods: Bone marrow aspirates were obtained from 48 patients with locally advanced (n = 11) or metastatic (n = 37) PDAC, before and after 2 months of chemotherapy. Disseminated tumor cells were detected with an mRNA panel and quantitative reverse transcription PCR. We used the highest levels measured in healthy bone marrow (n = 30) as a threshold to define the positive detection of disseminated tumor cells. Progression-free and overall survival were analyzed with Kaplan–Meier and Cox proportional hazards regression analyses.

Results: Disseminated tumor cells were detected in 15/48 (31%) bone marrow samples obtained before starting chemotherapy and in 8/25 (32%) samples obtained during chemotherapy. Patients with disseminated tumor cells detected before therapy had significantly shorter progression-free (p = 0.03; HR = 2.0) and overall survival (p = 0.03; HR = 2.0), compared to those without disseminated tumor cells in the bone marrow. When restricting disseminated tumor cell detection to keratins KRT7 and KRT8, the prognostic information was substantially stronger (p = 1 × 10^-6; HR = 22, and p = 2 × 10^-5; HR = 7.7, respectively). The multivariable Cox regression analysis demonstrated that disseminated tumor cell detection prior to treatment had independent prognostic value. In contrast, disseminated tumor cells detected during treatment did not have prognostic value.

Conclusions: Disseminated tumor cells detected before commencing chemotherapy had prognostic value in patients with inoperable PDAC.

Keywords: Disseminated tumor cells, DTC, Bone marrow, Survival, Prognosis, Pancreatic ductal adenocarcinoma, PDAC

*Correspondence: oddmund.nordgard@sus.no

© The Author(s) 2022. Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated in a credit line to the data.
of the disease is related to its late detection; over 80% of cases are diagnosed at an incurable stage [2]. Although recent multidrug treatments have significantly improved survival for patients with metastatic PDAC, the 5-year survival rate remains less than 5% [2, 3]. Hence, there is a striking need for enhanced diagnostics and treatment alternatives for this patient group.

PDAC metastasizes primarily to the liver, peritoneum, and lungs. Less than 1% of patients experience bone metastases [4, 5]. Nevertheless, there is evidence that disseminated tumor cells (DTCs) can be found in the bone marrow of patients with PDAC (reviewed in [6]). DTCs have primarily been detected with immunocytochemical methods that utilize various antibodies against keratin proteins [6–8]. However, in a few studies, reverse transcription PCR has also been used to detect DTCs indirectly, using keratin mRNAs as DTC markers [9–11]. Although some studies have demonstrated that DTC detection had prognostic value in PDAC, the results have been conflicting [6, 8]. The discrepancies may be related to the choice of DTC enrichment and detection methods, the choice of DTC markers and other methodological differences.

To clarify the prognostic value of DTCs in PDAC, in the present study, we used a sensitive method for detecting DTCs in bone marrow samples from patients with locally advanced or metastatic PDAC. This method involved multi-marker, reverse transcription, quantitative PCR (RT-qPCR) with pre-amplification. We investigated the prognostic value of DTCs detected both before and during chemotherapy, and the efficacy of using various DTC markers in this regard.

**Methods**

**Patients and samples**

We prospectively recruited 48 patients that had been treated for locally advanced (n=11) or metastatic (n=37) histologically confirmed PDAC at Stavanger University Hospital (n=42) or Haukeland (Bergen) University Hospital (n=6), between September 2012 and December 2020. The clinicopathological characteristics of the patients are shown in Table 1. Written informed consent was obtained from all participants, and the project was approved by the Regional Committee for Medical and Health Research Ethics (2011/475).

All patients were treated with chemotherapy according to Norwegian national guidelines [12]. Eighteen patients also received second-line treatments, after progression occurred on the first-line treatment. Treatment responses was monitored with radiological imaging, based on the RECIST 1.1 criteria [13].

For the present study, we collected patient follow-up data from medical records. Information on the time of death was also obtained from the hospital records, which were frequently updated, based on information from the National Registry in Norway. The last follow-up was recorded in June 2021, and the median follow-up time was 7.0 months (range 0.30–64 months).

Bone marrow samples (9 ml in EDTA tubes) were drawn unilaterally, from the posterior iliac crest under local anesthesia, before starting chemotherapy (n=48) and after eight weeks of treatment (n=25). In addition, bone marrow aspirates were obtained from 30 partially age-matched healthy individuals, which were included as a control group. The control group were self-reported free for any malignancy, had median age 54 years (range 22–69 years), and consisted of 20 women and 10 men, that signed a written informed consent.

Mononuclear cells were enriched from the bone marrow samples by Lymphoprep density gradient centrifugation. Isolated mononuclear cells were counted on a Countess II cell counter (Thermo Fisher Scientific), lysed in RLT buffer (Qiagen, 600 µl per 1E7 cells) with β-mercaptoethanol, and stored at −80 °C until further analysis.

**RNA isolation**

RNA was extracted from bone marrow lysates (600 µl, corresponding to 1 × 10⁷ cells) with the AllPrep DNA/RNA/Protein Mini kit (Qiagen), according to the protocol provided by the manufacturer. Extracted RNA was eluted in 40 µl of RNase-free water. The yield and purity were assessed with ultraviolet spectrophotometry, on a Nanodrop spectrophotometer.

**Marker selection**

Biomarkers for detecting DTCs were selected, based on findings in previous studies. These markers included mRNAs that encoded four keratins KRT7, KRT8, KRT18, and KRT19; carcinoembryonic antigen cell adhesion molecule-5 (CEACAM5), epithelial cellular adhesion molecule (EPCAM); the zinc finger and homeodomain transcription factor ZEB1; and the snail family transcriptional repressor 2 (SNAI2). We also performed bioinformatic analyses of publicly available mRNA expression data to identify any new markers. Briefly, we downloaded RNA expression data that was publicly available in the Human Protein Atlas [14, 15] in January 2021. We then filtered those data to select mRNAs that were expressed at high levels in normal pancreas and PDACs, but at very low levels in normal bone marrow and peripheral blood mononuclear cells. Candidate mRNAs (SPINK1, PRSS2, REG1A, MUC1, AGR2, TM4SF1) were validated experimentally, in a pilot study, in bone marrow samples from both healthy controls and patients. Only the mRNA that encoded
Table 1  Baseline patient characteristics stratified according to pre-treatment DTC status

| Variable                        | No. of patients [n = 48] | DTC positive [n = 15] | DTC negative [n = 33] | P value |
|---------------------------------|--------------------------|-----------------------|------------------------|---------|
| Median age (range)              |                          |                       |                        | 0.5     |
|                                | 67 [41–79]               | 63 [46–74]            | 67 [41–79]             |         |
| Sex (%)                         |                          |                       |                        | 0.5     |
| Female                          | 20 (42)                  | 5 (33)                | 15 (45)                |         |
| Male                            | 28 (58)                  | 10 (67)               | 18 (55)                |         |
| Primary tumor location (%)      |                          |                       |                        | 0.8     |
| Head                            | 19 (40)                  | 4 (27)                | 15 (45)                |         |
| Body                            | 7 (15)                   | 3 (20)                | 4 (12)                 |         |
| Tail                            | 7 (15)                   | 2 (13)                | 5 (15)                 |         |
| Unknowna                        | 15 (31)                  | 6 (40)                | 9 (27)                 |         |
| Clinical T stage (%)            |                          |                       |                        | 0.03    |
| T1                              | 1 (2)                    | 0 (0)                 | 1 (3)                  |         |
| T2                              | 14 (29)                  | 8 (53)                | 6 (18)                 |         |
| T3                              | 7 (15)                   | 3 (20)                | 4 (12)                 |         |
| T4                              | 20 (42)                  | 3 (20)                | 17 (52)                |         |
| Txa                             | 6 (13)                   | 1 (7)                 | 5 (15)                 |         |
| Clinical N stage (%)            |                          |                       |                        | 0.2     |
| N0                              | 19 (40)                  | 7 (47)                | 12 (36)                |         |
| N1                              | 16 (33)                  | 4 (27)                | 12 (36)                |         |
| N2                              | 3 (6)                    | 0 (0)                 | 3 (9)                  |         |
| Nx                              | 10 (21)                  | 4 (27)                | 6 (18)                 |         |
| Clinical M stage (%)            |                          |                       |                        | 0.5     |
| M0                              | 11 (23)                  | 2 (13)                | 9 (27)                 |         |
| M1                              | 37 (77)                  | 13 (87)               | 24 (73)                |         |
| Metastasis location (%)         |                          |                       |                        | 0.5     |
| Only liver                      | 24 (50)                  | 9 (60)                | 15 (45)                |         |
| Only lung                       | 3 (6)                    | 2 (13)                | 1 (3)                  |         |
| Multiple organsb                | 3 (6)                    | 1 (7)                 | 2 (6)                  |         |
| Peritoneal carcinomatosis        | 7 (15)                   | 1 (7)                 | 6 (18)                 |         |
| None                            | 11 (23)                  | 2 (13)                | 9 (27)                 |         |
| ECOG status (%)                 |                          |                       |                        | 0.5     |
| 0                               | 13 (27)                  | 3 (20)                | 10 (30)                |         |
| 1                               | 29 (60)                  | 10 (67)               | 19 (58)                |         |
| 2                               | 6 (13)                   | 2 (13)                | 4 (12)                 |         |
| First-line treatment (%)c       |                          |                       |                        | 0.3     |
| Gemcitabine                     | 5 (10)                   | 4 (27)                | 1 (3)                  |         |
| Gemcitabine + Abraxane          | 24 (50)                  | 7 (47)                | 17 (52)                |         |
| FOLFRINOX                       | 19 (40)                  | 4 (27)                | 15 (45)                |         |
| Second-line treatment (%)       |                          |                       |                        | 0.4     |
| Yes                             | 18 (38)                  | 4 (27)                | 14 (42)                |         |
| No                              | 30 (62)                  | 11 (73)               | 19 (58)                |         |
| Study site (%)                  |                          |                       |                        | 0.4     |
| Stavanger                       | 42 (88)                  | 12 (80)               | 30 (91)                |         |
| Bergen                          | 6 (13)                   | 3 (20)                | 3 (9)                  |         |

*a* Categories unknown and similar were not included in statistical testing  
*b* Not including carcinomatosis  
*c* Testing FOLFRINOX combination versus other treatments
serine peptidase inhibitor kazal type 1 (SPINK1) passed our evaluation criteria. The final selection of DTC markers is shown in Table 2.

Reverse transcription and pre-amplification
Reverse transcription was performed with 1 µg RNA in a total volume of 20 µl with the High-Capacity cDNA Reverse Transcription Kit (Applied Biosystems), according to the manufacturer’s protocol. Pre-amplification was performed to increase the sensitivity for rare mRNAs, in the setting of extensive subsampling. Briefly, cDNA (250 ng in 5 µl) from the transcripts of interest (Table 2) were pre-amplified in a total volume of 50 µl with the TaqMan® PreAmp Master Mix Kit (Applied Biosystems), in 14 amplification cycles, according to the manufacturer’s instructions. The pre-amplified cDNA was diluted to a final volume of 1000 µl.

Quantitative PCR
Pre-amplified cDNA was quantified in a LightCycler 480 Real-Time PCR System (Roche) with the TaqMan Gene Expression Master Mix (Applied Biosystems) and TaqMan gene expression assays (Applied Biosystems; Table 2), according to the manufacturer’s instructions. The TaqMan assays were all designed with probes or one of the primers spanning exons. Pre-amplified cDNA (5 µl or 6.25 µl; the same volume for whole PCR plates) was placed in a total volume of 25 µl in 96-well plates, and subjected to 40 additional amplification cycles. Cq values were determined with the fit-point method provided in the LightCycler 480 software version 1.5.1. Relative mRNA levels were computed with the \( \Delta \Delta C_q \) method [16], by normalizing against both the BCR reference transcript and a calibrator sample included on every plate. A bone marrow sample was considered to contain DTCs (positive DTC status), when the relative concentration of at least one of the mRNA markers was higher than the highest concentration observed for that marker in the healthy control group. To enhance visual comparability, the relative mRNA levels shown in Figs. 1 and 2 were normalized against the median level of each mRNA across all analyzed samples (both controls and patients).

Statistics
All statistical analyses were performed in Rstudio version 1.4.1103, with R version 4.0.4. Continuous data were compared with the Mann–Whitney test. Associations between categorical data were tested with Fisher’s exact test. Associations between ordered categorical data were examined with the Chi square test for trend.

The date of disease progression was defined as the date that the first radiologic imaging evaluation was scored as “Progressive Disease”, according to the RECIST 1.1 criteria [13]. Univariable survival was assessed with Kaplan–Meier survival estimates, log-rank tests, and univariable Cox regression. Multivariable Cox regression was performed to investigate the independent prognostic value of factors related to overall survival, with backward selection of the variables. Only variables with P-values below 0.1 in the univariable model were included in the initial multivariable model. These variables were: bone marrow DTC status, ECOG performance status (2 vs. 0 or 1), first-line treatment (FOLFIRINOX vs. any other), and clinical T (cT) stage (T4 vs. T1-3). The cT stage was not included in the final model, due to significant associations with two of the other variables. The proportional hazards assumption was checked with the cox.zph function in the survival R package. All tests were two-sided, and P-values <0.05 were considered statistically significant.

This manuscript was prepared according to the REMARK guidelines (recommendations for tumor marker prognostic studies) [17].

Results
Disseminated tumor cells in patients with unresectable PDAC
Bone marrow samples (\( n=73 \)) from 48 patients with locally advanced or metastatic PDAC (Table 1) were examined for the presence of DTCs by measuring the relative expression levels of epithelial and mesenchymal marker mRNAs with RT-qPCR (Fig. 1). We selected the KRT7, KRT8, KRT18, KRT19, CEACAM5, EPCAM, and SPINK1 transcripts as target mRNAs, because they were specifically expressed in epithelial cells. We selected ZEB1 and SNAI2 as target mRNAs, because they were mesenchymal-cell specific. We also analyzed...
bone marrow samples from 30 healthy control individuals to establish thresholds for distinguishing between altered and normal mRNA concentrations in bone marrow (Fig. 1). For each potential DTC marker, we set the highest mRNA level observed in normal bone marrow as the threshold. Based on those thresholds, we observed elevated mRNA levels in zero (SNAI2) to 20 (ZEB1) bone marrow samples from patients (Table 3). We found that the bone marrow relative levels of CEACAM5, SPINK1, and ZEB1 mRNAs were significantly higher in patient samples than in healthy control samples (p = 2 × 10^{-6}, p = 0.03, and p = 5 × 10^{-5}, respectively; Fig. 1). The levels of some markers (CEACAM5, KRT7, KRT8, KRT19, SPINK1) were correlated with each other, although mainly observed in a few samples (Fig. 2). On the other hand, the levels of the mesenchymal markers, SNAI2 and ZEB1, were not correlated with the other markers. Of the 73 bone marrow samples, 39 (53%) had elevated levels of at least one DTC marker.

Subsequent analyses demonstrated that the epithelial markers were most informative, from a clinical perspective. Thus, we combined the epithelial markers in a multi-marker panel. Among all samples, 23/73 (32%) showed at least one positive result on the panel, including 15/48 (31%) pre-treatment samples and 8/25 (32%) on-treatment samples (Table 3).

Next, we tested for associations between pre-treatment epithelial DTC status and the clinicopathological parameters shown in Table 1. We found that more patients with T2 tumors had DTC-positive samples (p = 0.03). Surprisingly, we also observed that more patients with T2 tumors had metastases (M1; P = 0.007), compared to patients with larger tumors. Moreover, the cT stage was associated with the type of first-line treatment (fewer patients with small tumors were treated with FOLFIRINOX; p = 0.02), but not with the ECOG status.

**Prognostic value of DTCs detected before treatment**

Patients were followed for a median of 7.0 months (range 0.30—64 months), which was also the median overall survival time (95% CI: 5.1—8.7 months). The median time to progression was 4.9 months (95% CI: 3.3—5.7 months). Patients with DTCs (based on the epithelial multi-marker assay) before starting chemotherapy had significantly shorter progression-free survival (p = 0.03; hazard ratio [HR] = 2.0; 95% CI: 1.1—3.7) and overall survival (p = 0.03; HR = 2.0; 95% CI: 1.1—3.8), compared to those without DTCs (Fig. 3A, B; Table 4). When patients were stratified according to single DTC markers, we found that KRT7 and KRT8 mRNA contributed most to survival probability (Supplementary Fig. 1). Therefore, we also assessed the progression-free (p = 1 × 10^{-6}, HR = 22) and overall survival (p = 2 × 10^{-5}, HR = 7.7) of patients positive for the combination of the KRT7 and KRT8 markers before chemotherapy and found their survival significantly shorter than the other patients’ survival (Fig. 3C and D, Table 4). When markers other than KRT7 and KRT8 were analyzed individually, none could identify patients with significantly shortened survival (Supplementary Fig. 1).

We performed a univariable Cox regression analysis to assess the prognostic value of pre-treatment bone marrow DTC status and the clinicopathological variables in Table 1. We found that the bone marrow DTC status, cT stage, ECOG status, and the type of first-line treatment were significantly associated with overall survival (Table 4). However, the cT stage was significantly associated with both bone marrow
Table 3  Number of BM samples positive for DTC markers

| Marker   | Positive samples pre-treatment (%) | Positive samples in treatment (%) | Positive samples in total (%) |
|----------|-----------------------------------|---------------------------------|-----------------------------|
| CEACAM5  | 1 (2)                             | 4 (16)                          | 5 (7)                       |
| EPCAM    | 2 (4)                             | 1 (4)                           | 3 (4)                       |
| KRT7     | 3 (6)                             | 1 (4)                           | 4 (5)                       |
| KRT8     | 5 (10)                            | 0 (0)                           | 5 (7)                       |
| KRT18    | 2 (4)                             | 0 (0)                           | 2 (3)                       |
| KRT19    | 2 (4)                             | 2 (8)                           | 4 (5)                       |
| SNAI2    | 0 (0)                             | 0 (0)                           | 0 (0)                       |
| SPINK1   | 7 (15)                            | 0 (0)                           | 7 (10)                      |
| ZEB1     | 15 (31)                           | 5 (20)                          | 20 (27)                     |
| At least one marker | 27 (56)                         | 12 (48)                         | 39 (53)                     |
| At least two markers | 7 (15)                          | 1 (4)                           | 8 (11)                      |
| At least three markers | 1 (2)                     | 0 (0)                           | 1 (1)                       |
| Epithelial multimarker | 15 (31)                     | 8 (32)                          | 23 (32)                     |
| Total number of samples | 48                            | 25                             | 73                          |

Fig. 2  Correlations between relative concentrations of DTC markers. The scatterplots on the left side of the matrix show the median-normalized relative concentrations of DTC markers, plotted on logarithmic axes. Pearson correlation coefficients are shown on the right side of the matrix; the colors and intensities indicate the direction and strengths of the correlations (green: $R = 1$, white: $R = 0$, blue: $R = -1$). Statistical significance is indicated with asterisks (**$p < 0.001$; $^{*}p < 0.05$). The plots placed on the diagonal show the data densities of the mRNAs indicated in the top bar.
DTC status and the type of first-line treatment; this situation represented a challenge for the multivariable Cox regression. Therefore, we excluded the cT stage from the multivariable analysis. The resulting multivariable model identified three variables with independent prognostic value: pre-treatment DTC status (HR = 2.0), ECOG performance status (HR = 6.7), and the type of first-line therapy (HR = 0.49; Table 5). When the cT stage was included in the model, neither the cT stage nor the DTC status were independent
significant predictors of survival. When DTC detection was restricted to only KRT7/8 measurements, the DTC status (HR = 7.9; 95% CI: 3.0–21) and ECOG performance status (HR = 6.5; 95% CI: 2.3–19) were the only independent significant predictors of overall survival.

### Prognostic value of DTCs detected during treatment

We assessed the prognostic value of DTCs detected after 2 months of chemotherapy. Kaplan–Meier survival estimates revealed no significant differences in progression-free or overall survival, according to in-treatment bone marrow DTC detection (Fig. 3E, F). The same result was obtained when DTC detection was restricted to the KRT7 and KRT8 markers; however, only one patient had elevated bone marrow KRT7 levels and none showed elevated KRT8 levels during treatment (Table 3).

### Discussion

This study demonstrated that RT-qPCR detection of DTCs before chemotherapy had prognostic value in patients with inoperable PDAC. The majority of previous studies utilized immunocytochemistry with pan-keratin antibodies to detect DTCs [6]. In studies that included patients with metastatic PDAC, the median rate of DTC-positive findings with immunocytochemistry was 34% (range 14–57) [7, 8, 18], which was quite close to our detection rate of 31% (Table 3) with the epithelial DTC multi-marker assay. In contrast, the only previous study that performed KRT19 RT-PCR for bone marrow DTC detection in PDAC did not identify any patients with DTCs [11]. This apparent discrepancy was probably due to their use of KRT19 mRNA as the only DTC marker; indeed, in the present study, the KRT19 mRNA marker only identified DTCs in 5% of our bone marrow samples (Table 3). Interestingly, KRT19 mRNA was previously used with great success for DTC detection in breast cancer, both in our research group and in other groups [19, 20]. Clearly, the choice and number of markers affect both the DTC detection rate and the prognostic value of the markers. This principle was demonstrated in the present study, when we restricted our analysis to KRT7 and KRT8 mRNA (reducing the DTC detection rate to 15%), and in other studies that performed immunocytochemistry with multiple antibodies [21].

The epithelial-to-mesenchymal transition was previously shown to be important for the metastatic process in solid cancers [22, 23]. Accordingly, mesenchymal markers have successfully been used to detect DTCs in breast cancer [24, 25]. However, our current results in PDAC demonstrated that the mesenchymal markers, SNAI2 and ZEB1, were not useful in identifying patients with shortened survival times. In the case of SNAI2 mRNA, this was due to high background expression levels in normal bone marrow samples. In the case of ZEB1, a large number of patient bone marrow samples had elevated mRNA levels (27%; Table 3), regardless of survival. Moreover, the median ZEB1 level in patient bone marrow samples was significantly higher than the median level observed in normal bone marrow samples (p = 5 × 10⁻⁵). Because the

### Table 4 Univariable Cox regression overall survival

| Variable                              | Hazard ratio (95% CI) | P value |
|---------------------------------------|-----------------------|---------|
| Pre-treatment BM DTC status           | 2.0 (1.1–3.7)         | 0.034   |
| Pre-treatment BM KRT7/8 DTC status    | 7.7 (3.0–20)          | 0.000024|
| Age (> 67 years)                      | 0.92 (0.50–1.7)       | 0.78    |
| Sex (Female vs male)                  | 0.82 (0.44–1.5)       | 0.54    |
| Clinical T stage (T4 vs T1/2/3)       | **0.49 (0.26–0.92)**  | 0.028   |
| Primary tumor localization (head/body vs tail) | 0.46 (0.20–1.1) | 0.07 |
| Clinical N stage (N1 vs N0)           | 0.82 (0.45–1.5)       | 0.52    |
| Clinical M stage (M1 vs M0)           | 1.52 (0.75–3.1)       | 0.25    |
| Metastatic sites (multiple organs vs single) | 0.98 (0.46–2.1) | 0.95 |
| ECOG status (2 vs 1/0)                 | **6.4 (2.3–18)**      | **0.00031**|
| First-line treatment (FOLFIRINOX vs other) | **0.47 (0.26–0.87)** | **0.0017** |

### Table 5 Multivariable Cox regression overall survival

| Variable                              | Hazard ratio (95% CI) | P value |
|---------------------------------------|-----------------------|---------|
| Pre-treatment BM DTC status           | 2.0 (1.0–3.8)         | 0.036   |
| ECOG status (2 vs 1/0)                 | **6.7 (2.3–19)**      | **0.00042**|
| First-line treatment (FOLFIRINOX vs other) | **0.49 (0.27–0.92)** | **0.027** |
high bone marrow ZEB1 mRNA levels were not related to clinical outcome, one might speculate whether the high ZEB1 levels might be caused by factors other than the presence of DTCs. KRT7 and KRT8 mRNA showed much stronger contributions to the prognostic value of DTC detection than the other epithelial markers (Supplemental Fig. 1 and Fig. 3C, D). Interestingly, we noticed that several previous immunocytochemistry studies that used the more narrow-targeted A45-B/B3 antibody (which target KRT7/8/18 [26, 27]) demonstrated that DTC detection had prognostic value in PDAC [7, 18]. In contrast, studies that used the less specific AE3/AE1 antibody cocktail (which target several acidic and basic keratins) failed to show any prognostic value for DTC detection in PDAC [8, 28]. Moreover, in a study on operable breast cancer, a direct comparison of these antibody cocktails demonstrated that DTC detection with the A45-B/B3 antibody had greater prognostic value than DTC detection with the AE3/AE1 antibody [27]. Thus, the choice of DTC markers appeared to affect the ability to identify patients with a poor prognosis. One explanation for this finding could be that different subgroups of DTCs with different keratin expression profiles might reflect different degrees of disease aggressiveness. Another explanation might be that some keratins might be expressed at higher levels in some healthy bone marrow cells, which would increase the rate of false-positive DTC detection [8]. Future experiments are required to clarify the value of different markers for DTC detection, to compare different detection technologies, and to define optimal standardized protocols for DTC detection in PDAC.

To our knowledge, this study was the first to examine DTCs both before and during chemotherapy in patients with PDAC. The proportion of DTC-positive bone marrow samples taken after 2 months of chemotherapy was similar to the corresponding proportion found in the pre-treatment samples (31% versus 32%; Table 3). However, the markers that contributed to DTC detection were quite different before and after treatment commenced. For example, only a single in-treatment sample (4%) showed elevated KRT7 or KRT8 concentration. Our findings suggested that KRT7 and KRT8 were the primary markers for identifying true DTCs or DTCs that reflected disease aggressiveness; thus, the strong reduction in KRT7/KRT8-positive samples during therapy may be related to treatment effects. This putative treatment effect might explain why DTC detection with all the epithelial markers lacked prognostic significance during chemotherapy. On the other hand, several previous studies have demonstrated that similar proportions of bone marrow samples were DTC-positive before and after chemotherapy, in both breast and ovarian cancers. Those findings suggested that chemotherapy did not effectively eradicate DTCs in those cancers [29–31]. Another hypothesis is that DTC dormancy may explain DTC persistence, chemoresistance, and late recurrences in breast cancer and other cancers (reviewed in [32, 33]). In PDAC, DTC dormancy might explain why DTCs could be observed in bone marrow samples, despite the rarity of bone metastases. Potentially, bone marrow is not a good “soil” for fostering PDAC cells, but dormancy mechanisms might enable survival in a suboptimal environment. Although DTCs, per se, might not form lethal metastases in PDAC, their presence in bone marrow appears to be associated with increased metastatic capacity in some patients, either due to direct tumor-cell seeding from the bone marrow [34] or because DTC survival in bone marrow is associated with increased metastatic capacity, in general.

Surprisingly, we observed a positive association between DTC detection and small primary tumors (T2) in our study cohort (P=0.03). Moreover, patients with small tumors displayed more metastatic disease (stage M1) and shorter overall survival, compared to patients with larger tumors (P=0.007; Table 4). Based on these observations, one might speculate that our DTC analysis identified a subgroup of patients with small, but particularly aggressive, primary tumors. Despite the established relationships between cT stage, M stage, and survival [35], other researchers have identified similar subgroups of patients with PDAC that have small, but aggressive, node-positive tumors [36]. However, due to the small size of our study cohort, these unexpected observations should be interpreted with caution.

Clinically, DTC detection might not be highly useful in metastatic PDAC, due to the extremely poor prognosis and limited treatment options for this patient group. However, DTCs have also been shown to provide prognostic information in the non-metastatic setting. In that setting, DTC detection might represent an approach for selecting patients that might benefit from adjuvant or neoadjuvant chemotherapy [7]. Clinical intervention studies are required to establish appropriate applications for DTC detection in the future.

Conclusions

This study showed that the detection of DTCs before initiating chemotherapy, but not during chemotherapy, could provide prognostic value in patients with unresectable PDAC. We found that the DTC markers KRT7 and KRT8 provided stronger prognostic information than other epithelial markers. In contrast, the investigated mesenchymal markers did not contribute to prognostic value. Further research is required to clarify the roles of different DTC markers, to optimize and standardize DTC
detection methods, and to establish the clinical utility of DTC detection in diagnostics.

Supplementary Information
The online version contains supplementary material available at https://doi.org/10.1186/s12885-022-09714-x.

Additional file 1: Supplementary Figure 1. Kaplan-Meier overall survival estimates stratified according to single DTC markers.

Acknowledgements
The authors express our deepest gratitude to the participating patients and their families. We also acknowledge the user representatives, Thor Viggo Aarrestad and Eirik Salvesen, for their input into the study design and result interpretation, and for continuously advocating the patient focus in the project. We also thank the funders and our collaborators in the Norwegian Cancer Society’s National Group of Expertise for Research on Pancreatic Cancer.

Authors’ contributions
ON designed the study, supervised the data collection, performed statistical analyses, and wrote the manuscript. ML participated in the laboratory data collection, data interpretation, and manuscript preparation. KT participated in the study design, data interpretation, and manuscript preparation. SO contributed to the study design, sample collection and processing, and manuscript preparation. KH collected clinical data and participated in the manuscript preparation. NBN and DF collected laboratory data and participated in the data analysis and manuscript preparation. HG participated in the study design, patient recruitment, clinical data collection, data interpretation, and manuscript preparation. NG recruited patients and reviewed the manuscript. RS participated in the study design, sample and data collection, interpretation of data, and manuscript preparation. BG participated in the study design, sample and data collection, interpretation of results, and manuscript preparation. All authors read and approved the final manuscript.

Funding
The project was funded by Stavanger University Hospital, the Western Norway Health authorities, the Folke Hermansen foundation, and the Norwegian Cancer Society (National Group of Expertise for Research on pancreatic cancer). None of the funding bodies influenced the design of the study, the collection, analysis, or interpretation of data, or the manuscript preparation.

Availability of data and materials
The datasets generated and analysed during the current study are not publicly available due to their sensitive nature (potentially identifying and sensitive personal information) and related limitations in the written informed consent (not mentioning public availability of collected data), but are available from the corresponding author on reasonable request.

Declarations
Ethics approval and consent to participate
Written informed consent was obtained from all participants. The study was performed in accordance with the Declaration of Helsinki and approved by the Regional Committee for Medical and Health Research Ethics (2011/475).

Consent for publication
Not applicable.

Competing interests
The authors declare no competing interests.

Author details
1 Department of Hematology and Oncology, Stavanger University Hospital, Stavanger, Norway. 2 Department of Chemistry, Bioscience and Environmental Technology, Faculty of Science and Technology, University of Stavanger, Stavanger, Norway. 3 Department of Oncology, Haukeland University Hospital, Bergen, Norway. 4 Present Address: Mosaic Oncology AS, Sandnes, Norway.

Received: 14 January 2022 Accepted: 24 May 2022
Published online: 03 June 2022

References
1. Sung H, Ferlay J, Siegel RL, Laversanne M, Soerjomataram I, Jemal A, et al. Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2021;71:209–49.
2. American Cancer Society. Cancer facts & figures. Atlanta: American Cancer Society; 2021.
3. Cancer Registry of Norway. Cancer in Norway 2020 - cancer incidence, mortality, survival and prevalence in Norway. Oslo: Cancer Registry of Norway; 2021.
4. Mackay TM, van Erning FN, van der Geest LGM, de Groot JW, Haj Mohammad N, Lemmens VE, et al. Association between primary organ (head, body and tail) of metastasised pancreatic ductal adenocarcinoma and oncologic outcome: A population-based analysis. Eur J Cancer. 1990;20(10):99–105.
5. He C, Huang X, Zhang Y, Lin X, Li S. The impact of different metastatic patterns on survival in patients with pancreatic cancer. Pancreatol Off J Int Assoc Pancreatol IAP. 2021;21:556–63.
6. Stephenson D, Nahm C, Chua T, Gill A, Mital A, de Reuver P, et al. Circulating and disseminated tumor cells in pancreatic cancer and their role in patient prognosis: a systematic review and meta-analysis. Oncotarget. 2017;8:107223–36.
7. Effenberger KE, Schroeder C, Eulenburg C, Reeh M, Tachezy M, Riethdorf S, et al. Disseminated tumor cells in pancreatic cancer - an independent prognosticator of disease progression and survival. Int J Cancer. 2012;131:E475–83.
8. Hugenschmidt H, Labori KJ, Brunborg C, Verbeke CS, Seebregt LT, Bendigten Schirmer C, et al. Cytokeratin-positive cells in the bone marrow from patients with pancreatic, periampullary malignancy and benign pancreatic disease show no prognostic information. BMC Cancer. 2020;20:1107.
9. Soeth E, Grigolet U, Moellmann B, Röder C, Schneidewind K, Kremer B, et al. Detection of tumor cell dissemination in pancreatic ductal carcinoma patients by CK20 RT-PCR indicates poor survival. J Cancer Res Clin Oncol. 2005;131:669–76.
10. Soeth E, Vogel I, Röder C, Juhl H, Marxsen J, Krüger U, et al. Comparative analysis of bone marrow and venous blood isolates from gastrointestinal cancer patients for the detection of disseminated tumor cells using reverse transcription PCR. Cancer Res. 1997;57:3106–10.
11. Hoffmann K, Kerner C, Wilpert W, Mueller M, Thiery J, Hauss J, et al. Detection of disseminated pancreatic tumor cells by amplification of cytokeratin-19 with quantitative RT-PCR in blood, bone marrow and peritoneal lavage of pancreatic carcinoma patients. World J Gastroenterol. 2007;13:2573–6.
12. Søreide JA, Grenbach JE, Gladhauge L, Lassen K, Dueland S, Smaaland R, et al. Nasjonalt handlingsprogram med retningslinjer for diagnostikk, behandling og oppfølging av pancreaskreft, 23.03.2017. Helsedirektoratet; 2017.
13. Eisenhauer EA, Therasse P, Bogaerts J, Schwartz LH, Sargent D, Ford R, et al. New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1). Eur J Cancer. 2009;45:228–47.
14. Uhlen M, Karlsson MJ, Zhong W, Tebani A, Pou C, Mikes J, et al. A genome-wide transcriptomic analysis of protein-coding genes in human blood cells. Science. 2019;366:eaaan9198.
15. Uhlen M, Zhang C, Lee S, Stojek E, Fagerberg L, Bidkhori G, et al. A pathology atlas of the human cancer transcriptome. Science. 2017;357:eaan2507.
16. Livak KJ, Schmittgen TD. Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) method. Methods. 2001;25:402–8.
17. McShane LM, Altman DG, Sauerbrei W, Taube SE, Gion M, Clark GM, et al. Reporting recommendations for tumor marker prognostic studies. J Clin Oncol. 2005;23:9067–72.
18. Thorban S, Roder JD, Siewert JR. Epithelial tumour cells in bone marrow of patients with pancreatic carcinoma detected by immunocytochemical staining. Eur J Cancer. 1990;26,3:363–5.
19. Farmen RK, Nordgård ON, Gilje B, Shammas FV, Kvaleøy JT, Oltedal S, et al. Bone marrow cytokeratin 19 mRNA level is an independent predictor of
relapse-free survival in operable breast cancer patients. Breast Cancer Res Treat. 2008;108:251–8.
20. Benoy IH, Elst H, Philips M, Wuyts H, Van Dam P, Scharpe S, et al. Real-time RT-PCR detection of disseminated tumour cells in bone marrow has superior prognostic significance in comparison with circulating tumour cells in patients with breast cancer. Br J Cancer. 2006;94:672–80.
21. Roder JD, Thorban S, Pantel K, Siewert JR. Micrometastases in bone marrow: prognostic indicators for pancreatic cancer. World J Surg. 1999;23:888–91.
22. Zhang Y, Weinberg RA. Epithelial-to-mesenchymal transition in cancer: complexity and opportunities. Front Med. 2018;12:361–73.
23. Ma B, Wells A, Clark AM. The pan-therapeutic resistance of disseminated tumor cells: role of phenotypic plasticity and the metastatic microenvironment. Semin Cancer Biol. 2020;60:138–47.
24. Watson MA, Ylagon LR, Trinkaus KM, Gillanders WE, Naughton MJ, Weilbaecher KN, et al. Isolation and molecular profiling of bone marrow micrometastases identifies TWIST1 as a marker of early tumor relapse in breast cancer patients. Clin Cancer Res. 2007;13:5001–9.
25. Tjensvoll K, Oftedal S, Farmen RK, Shammaa FV, Heikila R, Kvaløy JT, et al. Disseminated tumor cells in bone marrow assessed by TWIST1, cytokertatin 19, and mammaglobin A mRNA predict clinical outcome in operable breast cancer patients. Clin Breast Cancer. 2010;10:378–84. 
26. Waseem A, Karsten U, Leigh IM, Purks P, Waseem NH, Lane EB. Conformational changes in the rod domain of human keratin 8 following heterotypic association with keratin 18 and its implication for filament stability. Biochemistry. 2004;43:1283–95.
27. Effenberger KE, Borgen E, Eilenburg CZ, Barkowiak K, Grosser A, Synnestvedt M, et al. Detection and clinical relevance of early disseminated breast cancer cells depend on their cytokertatin expression pattern. Breast Cancer Res Treat. 2011;125:729–38.
28. Z'graggen K, Centeno BA, Fernandez-del Castillo C, Jimenez RE, Werner J, Warshaw AL. Biological implications of tumor cells in blood and bone marrow of pancreatic cancer patients. Surgery. 2001;129:537–46.
29. Wimberger P, Heubner M, Otterbach F, Fehm T, Kimmg R, Kasimir-Bauer S. Influence of platinum-based chemotherapy on disseminated tumor cells in blood and bone marrow of patients with ovarian cancer. Gynecol Oncol. 2007;107:331–8.
30. Synnestvedt M, Borgen E, Wist E, Wiedswang G, Weyde K, Risberg T, et al. Disseminated tumor cells as selection marker and monitoring tool for secondary adjuvant treatment in early breast cancer. Descriptive results from an intervention study. BMC Cancer. 2012;12:616.
31. Kasimir-Bauer S, Bittner A-K, König L, Reiter K, Keller T, Kimmg R, et al. Does primary neoadjuvant systemic therapy eradicate minimal residual disease? Analysis of disseminated and circulating tumor cells before and after therapy. Breast Cancer Res. 2016;18:20.
32. Banys-Paluchowski M, Reinhardt F, Fehm T. Disseminated tumor cells and dormancy in breast cancer progression. Adv Exp Med Biol. 2020;922:35–43.
33. Talukdar S, Bhooopathi P, Emadl D, Das S, Sarkar D, Fisher PB. Dormancy and cancer stem cells: an enigma for cancer therapeutic targeting. Adv Cancer Res. 2019;141:43–84.
34. Kim M-Y, Osikarsson T, Acharyya S, Nguyen DX, Zhang XH-F, Norton L, et al. Tumor self-seeding by circulating cancer cells. Cell. 2009;139:1315–26.
35. Amin S, Edge S, Greene FL, editors. AJCC cancer staging manual. 8th ed. New York: Springer; 2017.
36. Muralidhar V, Nipp RD, Mannon HJ, Punglia RS, Hong TS, Ferrone C, et al. Association between very small tumor size and decreased overall survival in node-positive pancreatic cancer. Ann Surg Oncol. 2018;25:4027–34.

Publisher's Note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.